the effect of paricalcitol on vascular calcification and cardiovascular disease in uremia beyond pth controlparicalcitol的影响在尿毒症除了甲状旁腺素血管钙化和心血管疾病控制.pdfVIP

SAGE-Hindawi Access to Research International Journal of Nephrology Volume 2011, Article ID 269060, 5 pages doi:10.4061/2011/269060 Review Article The Effect of Paricalcitol on Vascular Calcification and Cardiovascular Disease in Uremia: Beyond PTH Control Mario Cozzolino, Florjan Mehmeti, Paola Ciceri, Elisa Volpi, Andrea Stucchi, Irene Brenna, and Daniele Cusi Renal Division, DMCO, San Paolo Hospital, School of Medicine, University of Milan, Via A. di Rudinı 8; 20142, Milan, Italy ` Correspondence should be addressed to Mario Cozzolino, mariocozzolino@ Received 30 October 2010; Accepted 18 January 2011 Academic Editor: Biagio Raffaele Di Iorio Copyright © 2011 Mario Cozzolino et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Secondary hyperparathyroidism is a systemic disorder that associates with bone and cardiovascular disease, including arterial calcification. Treatment with calcitriol, the active form of vitamin D, reduces parathyroid hormone levels, but may result in elevations in serum calcium and phosphorus, increasing the risk of vascular calcification in dialysis patients. New vitamin D receptor activators (VDRAs) have been developed and investigated with the rationale to treat high serum PTH levels, with a reduced risk of hypercalcemia and hyperphosphatemia. Paricalcitol is a selective VDRA that suppresses PTH secretion with minimal increases on serum calcium and phosphate. Moreover, paricalcitol prevents vascular calcification in experimental mo